<?xml version="1.0" encoding="UTF-8"?>
<p>So far, current management often consists of off-label or compassionate therapies, antiparasitic agents including chloroquine, hydroxychloroquine and nitazoxanide, antibiotics, antiretroviral agents, anti-inflammatory and anti-coagulant compounds (heparin and heparin dervatives), and recently, the hyperimmune plasma from recovered patients [
 <xref rid="B10-microorganisms-08-01228" ref-type="bibr">10</xref>,
 <xref rid="B95-microorganisms-08-01228" ref-type="bibr">95</xref>]. Several clinical trials are underway to examine existing antiviral drugs and to identify those that could be specific and effective against COVID-19. PubMed, Embase, and Google Scholar were searched to identify articles that supported therapeutic benefit for a pharmacological substance in SARS-CoV-1 or MERS-CoV that could be repositioned for treatment of SARS-CoV-2 infections. 
</p>
